

EXPRESS MAIL NO. EV334001414US

**INFORMATION
DISCLOSURE STATEMENT**

Address to:
Mail Stop PATENT APPLICATION
Commissioner for Patents
P.O. Box 1450
Arlington, VA 22212-1450

Attorney Docket	UCSF-088CON2
First Named Inventor	STERN, ROBERT
Application Number	To Be Assigned
Confirmation No.	To Be Assigned
Filing Date	July 18, 2003
Group Art Unit	To Be Assigned
Examiner Name	To Be Assigned
Title:	"HUMAN PLASMA HYALURONIDASE"

Sir:

This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-SB/08A listing the references and copies of the cited references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.


All of the references identified herein were disclosed in parent application serial number 09/795,914, filed 2/27/2001 and as such, copies thereof are not included pursuant to the provisions of 37 CFR § 1.98(d).

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C. § 102.

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815, Order No. UCSF-088CON2 may be charged thereon.

Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP

Date: July 18, 2003

By: 
Paula A. Borden
Registration No. 42,344

BOZICEVIC, FIELD & FRANCIS LLP
200 Middlefield Road, Suite 200
Menlo Park, CA 94025
Telephone: (650) 327-3400
Facsimile: (650) 327-3231

INFORMATION DISCLOSURE CITATION Form PTO-1449 (Modified) <i>(Use several sheets if necessary)</i>	ATTY. DOCKET NO. UCSF088CON	SERIAL NO. 09/795,914
	APPLICANT Stern et al.	
	FILING DATE February 27, 2001	GROUP 1642

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
AA	3,945,889	03/23/1976	Mima et al.			
AB	5,427,779	06/27/1995	Elsner et al.			

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass	Translation
AC WO 88/02261	04/07/88	PCT			Yes No
AD WO 89/05329	06/15/89	PCT			
AE WO 96/03497	02/08/96	PCT			

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AF	Afify et al., (1993) "Purification and Characterization of Human Serum Hyaluronidase" Arch. Biochem. Biophys. 305 (2):434-441.
AG	Baumgartner et al., (1988) "Phase I Study in Chemoresistant Loco-regional Malignant Disease with Hyaluronidase" Reg. Cancer Treat. 1:55-58.
AH	Beckenlehner et al., (1992) "Hyaluronidase Enhances the Activity of Adriamycin in Breast Cancer Models in Vitro and in Vivo" J. Cancer Res. Oncol. 118:591-596.
AI	Bonner et al., (1966) "Colorimetric Method for Determination of Serum Hyaluronidase Activity" Clinica Chimica Acta 13:746-752.
AJ	Bordier, (1981) "Phase Separation of Integral Membrane Proteins in Triton X-114 Solution" J. Biol. Chem. 256(4):1604-1607.
AK	Cashman et al., (1969) "The Hyaluronidase of Rat Skin" Arch. Biochem. Biophys. 135:387-395.
AL	Czejka et al., (1990) "Influence of hyaluronidase on the blood plasma levels of 5-fluorouracil in patients," Pharmazie 45:H.9.
AM	De Maeyer et al., (1992) "The Growth Rate of Two Transplantable Murine Tumors, 3LL Lung Carcinoma and B16F10 Melanoma, Is Influenced by Hyal-1, A Locus Determining Hyaluronidase Levels and Polymorphism" Int. J. Cancer 51:657-660.
AN	De Salegui et al., (1967) "A Comparison of Serum and Testicular Hyaluronidase" Arch. Biochem. Biophys. 121:548-554.
AO	Delpech et al., (1987) "An Indirect Enzymeimmunoassay for Hyaluronidase" J. Immunol. Methods 104:223-229.
AP	Doctor et al., (1983) "Isolation and Properties of a New Anticoagulant Protein from Commercial Bovine Testicular Hyaluronidase" Thrombosis Res. 30:565-571.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

INFORMATION DISCLOSURE CITATION Form PTO-1449 (Modified) <i>(Use several sheets if necessary)</i>		ATTY. DOCKET NO. UCSF088CON	SERIAL NO. 09/795,914
		APPLICANT Stern et al.	
		FILING DATE February 27, 2001	GROUP 1642
AQ	Dorfman et al., (1948) "A Turbidimetric Method for the Assay of Hyaluronidase" J. Biol. Chem. 172:367-375.		
AR	Fenger et al (1982) "Purification of Human Serum Hyaluronidase Using Chromatofocusing." (J. Chromatogr. 240:173-179)		
AS	Fischer-Szafarz et al., (1989) "Hyal-1, a Locus Determining Serum Hyaluronidase Polymorphism, in Chromosome 9 in Mice" Somat. Cell. Mol. Genet. 15:79-83.		
AT	Fischer-Szafarz et al., (1995) "Hyaluronidase in Human Somatic Tissues and Urine: Polymorphism and the Activity in Diseases," Acta Biochim Pol. 42:31-3.		
AU	Gabizon (1995) "Stealth Liposomes and Cancer Targeting: A Realistic Compromise in Drug Delivery." (J. Liposome Res., 5:704-710)		
AV	GenBank accession No. U03056, deposited Nov. 1, 1993.		
AW	Gregoriadis et al. (1993) "Liposomes in drug delivery. Clinical, diagnostic and ophthalmic potential." (Drugs, 45:15-28)		
AX	Guntenhoner et al., (1992) "A Substrate-Gel Assay for Hyaluronidase Activity" Matrix 12:388-396.		
AY	Harrison et al., (1988) "Multiple Forms of Ram and Bull Sperm Hyaluronidase Revealed by Using Monoclonal Antibodies" J. Reprod Fertil. 82:777-785.		
AZ	Hegi et al., (1994) "Allelotyping Analysis of Mouse lung Carcinomas Reveals Frequent Allelic Losses on Chromosome 4 and an Association between Allelic Imbalances on Chromosome 6 and K-ras Activation," Cancer Research 54, pp. 6257-6264.		
BA	Horn et al., (1985) "Intravesical Chemotherapy of Superficial Bladder Tumors in a Controlled Trial with Cis-Platinum Versus Cis-Platinum Plus Hyaluronidase" J. Surg. Oncol. 28:304-307.		
BB	Johnstone et al. (1987) (Immunocytochemistry in Practice, Blackwell Scientific Publications, Oxford, pp. 30-31)		
BC	Kimata et al., (1983) "Increased Synthesis of Hyaluronic Acid by Mouse Mammary Carcinoma Cell Variants with High Metastatic Potential" Cancer Res. 43:1347-1354.		
BD	Kohn et al., (1994) "Effects of Hyaluronidase on Doxorubicin Penetration into Squamous Carcinoma Multicellular Tumor Spheroids and Its Cell Lethality" J. Cancer Res. Clin. Oncol. 120:293-297.		
BE	Kolarova et al., (1970) "Host-Tumour Relationship XXIX. Hyaluronidase Activity and Seromucoid Concentration in Blood Serum of Patients with Cancer" Neoplasma 17:641-648.		
BF	Komender et al., (1973) "Isolation of Hyaluronidase from Kidney Extract," Bull Acad. Pol. Sci. (Biol.) 21:637-41.		
BG	Kreil, (1995) "Hyaluronidases--A Group of Neglected Enzymes" Protein Sci. 4:1666-1669.		
BH	Levy et al., (1966) "Mammalian Glycosidases and Their Inhibition by Aldonolactones" Method Enzymol. 8:571-584.		
BI	Lien et al., (1990) "Collagen, Proteoglycan and Hyaluronidase Activity in Cultures from Normal and Scoliotic Chicken Fibroblasts" Biochim. Biophys. Acta. 1034:318-325.		
BJ	Liu et al., (1996) "Expression of Hyaluronidase by Tumor Cells Induces Angiogenesis In Vivo" Proc. Natl. Acad. Sci. USA 93 (15):7832-7837.		
BK	Margolis et al., (1972) "The Hyaluronidase of Brain," J. Neurochem. 19:2325-32.		
BL	Natowicz et al., (1996) "Clinical and Biochemical Manifestations of Hyaluronidase Deficiency" N. Engl. J. Med. 335 (14):1029-1033.		

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

INFORMATION DISCLOSURE CITATION Form PTO-1449 (Modified) <i>(Use several sheets if necessary)</i>		ATTY. DOCKET NO. UCSF088CON	SERIAL NO. 09/795,914
		APPLICANT Stern et al.	
		FILING DATE February 27, 2001	GROUP 1642
BM	Natowicz, et al., (1996) "Human Serum Hyaluronidase: Characterization of a Clinical Assay," Clinical. Chimica. Acta., 245:1-6		
BN	Northrup et al., (1973) "Development of the Hyaluronidase Activity Assay As A Cancer Screening Test" Clin. Biochem. 6:220-228.		
BO	Palowski et al., (1981) "The Effects of Hyaluronidase Upon Tumor Formation in BALB/c Mice Irradiated with Ultraviolet Light" Carcinogenesis (Proceedings of the 17th Annual Meeting of the American Society of Clinical Oncology), Washington, D.C., 22:105, (abstract 415).		
BP	Pawlowski et al., (1979) "Effects of Hyalurodinase Upon Tumor Formation in BALB c Mice Painted with 7,12-Dimethylbenz-(α)Anthracene" Int. J. Cancer 23:105-109.		
BQ	Reissig et al., (1955) "A Modified Colorimetric Method for the Estimation of N-Acetyl amino Sugars" J. Biol. Chem. 217:959-966.		
BR	Ruggiero et al., (1987) "Hyaluronidase Activity of Rabbit Skin Wound Granulation Tissue Fibroblasts" J. Dent. Res. 66(7):1283-1287.		
BS	Scheithauer et al., (1988) "In Vitro Evaluation of the Anticancer Drug Modulatory Effect of Hyaluronidase in Human Gastrointestinal Cell Lines" Anticancer Res. 8:391-396.		
BT	Schuller et al., (1991) "Pharmacokinetics of Intrahepatic 5-Fluorouracil \pm Preinjected Hyaluronidase (Neopermease, N)" Proc. Amer. Assoc. Cancer Res. 32:173, (Abstract No. 1034).		
BU	Stern et al., (1992) "An Elisa-Like Assay for Hyaluronidase and Hyaluronidase Inhibitors" Matrix 12:397-403.		
BV	Thet et al., (1983) "Changes in Lung Hyaluronidase Activity Associated with Lung Growth, Injury and Repair" Biochem. Biophys. Res. Commun. 117:71-77.		
BW	Underhill, (1991) "CD44: The Hyaluronan Receptor" J. Cell Science 103:293-298.		
BX	van den Berg et al., (1995) "Exogenous Glycosyl Phosphatidylinositol-anchored CD59 Associates with Kinases in Membrane Clusters on U937 Cells and Becomes Ca ²⁺ -signaling Competent" J. Cell Biology 131(3):669-677.		
BY	Wolf et al., (1982) "The Serum Kinetics of Bovine Testicular Hyaluronidase in Dogs, Rats and Humans" J. Pharmacol. Exper. Therap. 222(2):331-337.		
BZ	Zanker et al., (1986) "Induction of Response in Previous Chemotherapy Resistant Patients by Hyaluronidase" Proc. Amer. Assoc. Cancer Res. 27:390 (Abstract 1550).		

F:\forms\word 2k forms\form PTO-1449.doc

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/795,914
				Filing Date	February 27, 2001
				First Named Inventor	STERN, ROBERT
				Group Art Unit	1632
				Examiner Name	CHEN, LIPING
Sheet	1	of	1	Attorney Docket Number	UCSF-088CON

U.S. PATENT DOCUMENTS						
Examiner Initials [*]	Cite No. ¹	U.S. Patent Documents		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials [*]	Cite No. ¹	Foreign Patent Documents			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
		WO	96/31596	A1	Stern <i>et al.</i>	10-10-1996		

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard St.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Notice of References Cited	Application/Control No. 09/795,914	Applicant(s)/Patent Under Reexamination STERN ET AL.	
	Examiner Liping Chen	Art Unit 1632	Page 1 of 3

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-			
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Verma, I. M. et al. "Gene Therapy- promises, Problems and Prospects" (1997) Nature Vol. 389, pp. 239-242.
	V	Orkin, S. H. et al. "Report and Recommendations of The Panel to Assess The NIH Investment in Research on Gene Therapy" (1995)
	W	Eck, S. L. et al "Gene-Based therapy" in The Pharmacological Basis of therapeutics, Goodman & Gilman's, McGraq-Hill, Ninth Edition, pp. 77-101, 1996.
	X	Rozenberg, Y. et al. "Alternative Gene Delivery" S.T.P. Pharma Sci (2001) Vol. 11, pp. 21-30.

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

Notice of References Cited	Application/Control No. 09/795,914	Applicant(s)/Patent Under Reexamination STERN ET AL.	
	Examiner Liping Chen	Art Unit 1632	Page 2 of 3

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-			
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Nishikawa, M. et al. "Nonviral Vectors in The New Millennium: Delivery Barrier in Gene Transfer" (2001) Hum Gene Ther Vol. 12, pp. 861-870.
	V	Balicki, D. et al. "Gene Therapy of Human Disease" (2002) Medicine Vol. 81, pp. 69-86.
	W	Csoka, T. B. et al. "Hyaluronidases in Tissue Invasion" (1997) Invasion and Metastasis Vol. 17, No. 6, pp. 297-311.
	X	Chang N. S. "Transforming Growth Factor-beta Protection of Cancer Cells Against Tumor Necrosis Factor Cytotoxicity is counteracted by Hyaluronidase" (1998) Int J Mol Med Vol. 2, No. 6, pp. 653-659.

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
 Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

Notice of References Cited	Application/Control No. 09/795,914	Applicant(s)/Patent Under Reexamination STERN ET AL.	
	Examiner Liping Chen	Art Unit 1632	Page 3 of 3

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-			
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Lepperdinger, G. et al. "Hyal2 - Less Active, But Nore Versatile?" (2001) Matrix Biol Vol. 20, pp. 509-514.
	V	
	W	
	X	

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

Notice of References Cited

Application/Control No.

09/795,914

Applicant(s)/Patent Under
Reexamination
STERN ET AL.

Examiner

Quang Nguyen, Ph.D.

Art Unit

1636

Page 1 of 1

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-			
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Lin Ji et al. Expression of several genes in the human chromosome 3p21.3 homozygous deletion region by an adenovirus vector results in tumor suppressor activities in Vitro and in Vivo. Cancer Res. 62:2715-2720, 2002.
	V	
	W	
	X	

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.